New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study |
| |
| Authors: | Jhen-Hao Jhan Hsin-Chih Yeh Yu-Han Chang Shiao-Jin Guu Wen-Jeng Wu Yii-Her Chou Ching-Chia Li |
| |
| Affiliation: | 1. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;2. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;3. Management Offices, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;4. Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;5. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan |
| |
| Abstract: | IntroductionAndrogen-deprivation therapy (ADT) is important in the treatment of prostate cancer. However, the relationship between ADT and the risk of diabetes remains unclear, and the association between duration and types of ADT has not been fully investigated.AimTo examine the risk of developing type 2 diabetes mellitus (T2DM) in men who underwent ADT for prostate cancer.MethodsData were collected retrospectively from the Longitudinal Health Insurance Database of Taiwan. In total, 4604 prostate cancer patients ≥40?years old who underwent ADT were included in the study cohort, and 4604 prostate cancer patients without ADT were included as controls, after adjusting for age and other comorbidities.ResultsDuring the four-year follow-up period, the incidence of new-onset T2DM was 27.49 and 11.13 per 1000 person-years in the ADT and ADT-never cohorts, respectively. The ADT cohort was 2.19 times more likely to develop T2DM than the control group (95% CI 1.90–2.53, P? ConclusionsMen with prostate cancer who received ADT are at risk for developing diabetes. |
| |
| Keywords: | Prostate cancer Androgen-deprivation therapy Complete Androgen Blockade (CAB) Type 2 diabetes (T2DM) Insulin resistance Insulin deficiency |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
